Subcontract for Strategies and Treatments for Respiratory and Viral Emergencies Study Payments (STRIVE)

Abstract Respiratory infections remain a threat to public health, as highlighted by the coronavirus disease 2019 (COVID-19) pandemic. They may circulate endemically, but may also lead to smaller outbreaks, epidemics, and pandemics. Current threats for epidemic and pandemic spread include the viral pathogens SARS-CoV-2 and influenza. Additionally, it is likely that novel respiratory pathogens will emerge. Currently, while most cases of SARS-CoV-2 and influenza infection are mild, progressive disease can result in hospitalization, requirement for organ supportive care including mechanical ventilation, and substantial morbidity and mortality. The most common mode of disease progression is respiratory failure following the development of pneumonia. However, other severe complications may be caused from thromboembolic disease involving lung, heart and other organs, as well as failure of kidney, liver and central nervous function, and emerging complicating infections (“superinfections”). Several clinical trials investigating novel drugs and repurposed older agents for the treatment of adults hospitalized with COVID-19 and influenza have been completed in the past and are ongoing. The standard of care is hence evolving rapidly. In contrast, for novel pathogens the potential treatment landscape will need to be defined. STRIVE aims to provide an agile research platform able to investigate strategies and treatments that may improve the health of patients hospitalized with a respiratory infection.